Published in Antimicrob Agents Chemother on October 17, 2011
Volatile metabolites of pathogens: a systematic review. PLoS Pathog (2013) 1.20
Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother (2012) 1.20
Bloodstream infections in intensive care unit patients: distribution and antibiotic resistance of bacteria. Infect Drug Resist (2015) 1.00
Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother (2013) 0.97
Effect of statin therapy in the outcome of bloodstream infections due to Staphylococcus aureus: a prospective cohort study. PLoS One (2013) 0.93
Clinical management of infections caused by multidrug-resistant Enterobacteriaceae. Ther Adv Infect Dis (2013) 0.88
Bloodstream infections and sepsis in Greece: over-time change of epidemiology and impact of de-escalation on final outcome. BMC Infect Dis (2014) 0.86
Stratification of the impact of inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by predicted prognosis. Antimicrob Agents Chemother (2014) 0.83
Treatment of bloodstream infections in ICUs. BMC Infect Dis (2014) 0.82
Volatile organic compound analysis by ion molecule reaction mass spectrometry for Gram-positive bacteria differentiation. Eur J Clin Microbiol Infect Dis (2012) 0.82
The impact of healthcare-associated infection on mortality: failure in clinical recognition is related with inadequate antibiotic therapy. PLoS One (2013) 0.80
Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome. Eur J Clin Microbiol Infect Dis (2014) 0.79
Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-onset Bacteremia in Comparison with Third-generation Cephalosporin Therapy. Antimicrob Agents Chemother (2016) 0.78
Prediction of Fluoroquinolone Resistance in Gram-Negative Bacteria Causing Bloodstream Infections. Antimicrob Agents Chemother (2016) 0.78
Bloodstream infections in internal medicine. Virulence (2016) 0.78
Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study. BMC Infect Dis (2013) 0.78
Delays in appropriate antibiotic therapy for gram-negative bloodstream infections: a multicenter, community hospital study. PLoS One (2013) 0.77
Identification of pathogens from blood culture bottles in spiked and clinical samples using matrix-assisted laser desorption ionization time-of-flight mass-spectrometry analysis. BMC Res Notes (2014) 0.75
High Frequency of Clinically Significant Bacteremia in Adults Hospitalized With Falciparum Malaria. Open Forum Infect Dis (2016) 0.75
Epidemiology and microbiology of nosocomial bloodstream infections: analysis of 482 cases from a retrospective surveillance study. J Zhejiang Univ Sci B (2015) 0.75
The Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the Evidence. Infect Dis Rep (2017) 0.75
De-escalation, adequacy of antibiotic therapy and culture positivity in septic patients: an observational study. Rev Bras Ter Intensiva (2016) 0.75
Electronic Alerts with Automated Consultations Promote Appropriate Antimicrobial Prescriptions. PLoS One (2016) 0.75
Gram-negative and -positive bacteria differentiation in blood culture samples by headspace volatile compound analysis. J Biol Res (Thessalon) (2016) 0.75
Methodology in improving antibiotic implementation policies. World J Methodol (2016) 0.75
Antimicrobial use and microbiological testing in district general hospital ICUs of the Veneto region of north-east Italy. Eur J Clin Microbiol Infect Dis (2016) 0.75
Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections. Infection (2017) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med (2003) 28.68
CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control (2008) 24.70
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 14.36
Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med (2002) 8.67
Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med (1991) 5.85
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med (2004) 4.75
Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med (2003) 4.56
Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. N Engl J Med (2009) 4.42
Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med (1989) 3.98
Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) (2003) 3.66
A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis (2007) 3.51
Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis (2010) 2.76
Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother (2010) 2.34
Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality. Intern Med J (2001) 1.83
Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. Infect Control Hosp Epidemiol (2003) 1.75
[Acinetobacter baumannii bacteremia: clinical and prognostic features]. Enferm Infecc Microbiol Clin (2003) 1.61
Bloodstream infections: evolution and trends in the microbiology workload, incidence, and etiology, 1985-2006. Medicine (Baltimore) (2008) 1.27
Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother (2008) 1.22
Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores. Clin Microbiol Infect (2006) 1.17
Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin Microbiol Infect (2010) 1.15
Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis (2003) 1.01
Propensity-matched analysis of appropriate empirical antibiotic treatment. Clin Infect Dis (2007) 0.89
[Guidelines for the diagnosis and treatment of patients with bacteriemia. Guidelines of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica]. Enferm Infecc Microbiol Clin (2007) 0.85
Current management of bloodstream infections. Expert Rev Anti Infect Ther (2010) 0.83
Septic shock should be included in multivariable models analyzing the effect of empirical antibiotic therapy on mortality. Clin Infect Dis (2007) 0.80
Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis (2006) 3.79
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis (2009) 3.17
Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis (2013) 3.06
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology (2007) 2.39
[Epidemiology, clinical features and prognosis of infections due to Stenotrophomonas maltophilia]. Enferm Infecc Microbiol Clin (2006) 2.09
High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int (2008) 2.04
Knowledge and perceptions of junior and senior Spanish resident doctors about antibiotic use and resistance: results of a multicenter survey. Enferm Infecc Microbiol Clin (2012) 1.70
Assessing the influence of risk factors on rates and dynamics of peripheral vein phlebitis: an observational cohort study. Med Clin (Barc) (2012) 1.54
Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort. Clin Infect Dis (2013) 1.52
[Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000)]. Enferm Infecc Microbiol Clin (2004) 1.41
Endoglin as a marker in cervical paragangliomas. Head Neck (2010) 1.39
National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. J Antimicrob Chemother (2011) 1.38
[Clinical status, adherence to HAART and quality of life in HIV-infected patients receiving antiretroviral treatment]. Enferm Infecc Microbiol Clin (2005) 1.30
Dengue vector dynamics (Aedes aegypti) influenced by climate and social factors in Ecuador: implications for targeted control. PLoS One (2013) 1.19
Four main virotypes among extended-spectrum-β-lactamase-producing isolates of Escherichia coli O25b:H4-B2-ST131: bacterial, epidemiological, and clinical characteristics. J Clin Microbiol (2013) 1.17
Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli. Clin Infect Dis (2009) 1.16
Dalbavancin or oritavancin for skin infections. N Engl J Med (2014) 1.14
Risk factors and prognosis of catheter-related bloodstream infection in critically ill patients: a multicenter study. Intensive Care Med (2008) 1.14
Diversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study. J Clin Microbiol (2010) 1.09
[Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)]. Enferm Infecc Microbiol Clin (2009) 1.07
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother (2008) 1.05
Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS (2010) 1.04
Biofilm formation at the solid-liquid and air-liquid interfaces by Acinetobacter species. BMC Res Notes (2011) 1.03
Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci (2010) 1.03
Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother (2013) 1.01
Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect (2011) 1.00
Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother (2011) 1.00
Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother (2013) 0.97
Genetic variability among ampC genes from acinetobacter genomic species 3. Antimicrob Agents Chemother (2008) 0.97
Spanish multicenter study of the epidemiology and mechanisms of amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob Agents Chemother (2012) 0.94
Characterisation of clinical and food animal Escherichia coli isolates producing CTX-M-15 extended-spectrum β-lactamase belonging to ST410 phylogroup A. Int J Antimicrob Agents (2011) 0.92
[Prevalence of the tetA and tetB genes as mechanisms of resistance to tetracycline and minocycline in Acinetobacter baumannii clinical isolates]. Enferm Infecc Microbiol Clin (2006) 0.92
[Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica]. Enferm Infecc Microbiol Clin (2009) 0.91
[In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010]. Enferm Infecc Microbiol Clin (2012) 0.90
Evaluation of the Etest method for fosfomycin susceptibility of ESBL-producing Klebsiella pneumoniae. J Antimicrob Chemother (2007) 0.89
Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal. Medicine (Baltimore) (2014) 0.88
Spondylodiscitis in patients under haemodyalisis. Int Orthop (2011) 0.88
"The 3/3 strategy": a successful multifaceted hospital wide hand hygiene intervention based on WHO and continuous quality improvement methodology. PLoS One (2012) 0.88
Analysis of plasmids encoding extended-spectrum beta-lactamases (ESBLs) from Escherichia coli isolated from non-hospitalised patients in Seville. Int J Antimicrob Agents (2007) 0.88
Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes. Medicine (Baltimore) (2011) 0.87
Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. Chest (2011) 0.87
Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg (2004) 0.87
Multidrug-resistant Acinetobacter baumannii: eyes wide shut? Enferm Infecc Microbiol Clin (2008) 0.86
Escherichia coli O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. Enferm Infecc Microbiol Clin (2012) 0.86
[Guidelines for the diagnosis and treatment of patients with bacteriemia. Guidelines of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica]. Enferm Infecc Microbiol Clin (2007) 0.85
Prognostic factors in left-sided endocarditis: results from the Andalusian multicenter cohort. BMC Infect Dis (2010) 0.85
Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study. Clin Infect Dis (2003) 0.85
Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Clin Transl Oncol (2010) 0.84
Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies. Future Microbiol (2014) 0.84
Surgery of vagal paragangliomas: six patients and review of literature. Surg Oncol (2008) 0.83
Clinical features of infections and colonization by Acinetobacter genospecies 3. J Clin Microbiol (2010) 0.83
Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clin Infect Dis (2009) 0.83
Current management of bloodstream infections. Expert Rev Anti Infect Ther (2010) 0.83
Deep venous thrombosis associated with pulmonary tuberculosis and transient protein S deficiency. Scand J Infect Dis (2002) 0.82
Neonatal sepsis caused by a CTX-M-32-producing Escherichia coli isolate. J Med Microbiol (2008) 0.81
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients. Eur J Intern Med (2013) 0.80
[Candidemias: multicentre analysis in 16 hospitals in Andalusia (Spain)]. Enferm Infecc Microbiol Clin (2011) 0.80
Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients. AIDS Patient Care STDS (2011) 0.80
Prognosis of 2009 A(H1N1) influenza in hospitalized pregnant women in a context of early diagnosis and antiviral therapy. Antivir Ther (2011) 0.79
Seroprevalence of antibodies to the influenza A (H1N1) virus among healthcare workers prior to the 2009 pandemic peak. Enferm Infecc Microbiol Clin (2012) 0.79
Epidemiological and clinical features associated with colonisation/infection by Acinetobacter baumannii with phenotypic heterogeneous resistance to carbapenems. Int J Antimicrob Agents (2012) 0.79
Etiology of spontaneous pneumothorax in 105 HIV-infected patients without highly active antiretroviral therapy. Eur J Radiol (2008) 0.78
Isolation of multidrug-resistant Klebsiella oxytoca carrying blaIMP-8, associated with OXY hyperproduction, in the intensive care unit of a community hospital in Spain. J Antimicrob Chemother (2010) 0.78
Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study. BMC Infect Dis (2013) 0.78
A dynamic in vitro model for evaluating antimicrobial activity against bacterial biofilms using a new device and clinical-used catheters. J Microbiol Methods (2010) 0.78
Successful multifaceted intervention aimed to reduce short peripheral venous catheter-related adverse events: a quasiexperimental cohort study. Am J Infect Control (2012) 0.78
Ankle-brachial index in HIV infection. AIDS Res Ther (2009) 0.78
Similarities between the genetic environments of blaCTX-M-15 in Escherichia coli from clinical and food samples from Spain and overseas travellers. J Antimicrob Chemother (2011) 0.78
Control measures for Acinetobacter baumannii: a survey of Spanish hospitals. Enferm Infecc Microbiol Clin (2010) 0.77
[Impact of demographic and psychosocial factors on adherence to antiretroviral treatment]. Enferm Infecc Microbiol Clin (2006) 0.77
[Community-onset and nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus in Spanish hospitals]. Enferm Infecc Microbiol Clin (2009) 0.77
Prudent use of antimicrobials: have we done the best we can? The SEIMC and REIPI statement. Enferm Infecc Microbiol Clin (2010) 0.76
Scientific evidence and research in antimicrobial stewardship. Enferm Infecc Microbiol Clin (2013) 0.76
Relapsing blepharitis in patients under highly active antiretroviral therapy including indinavir. AIDS (2004) 0.76
How to assist clinicians in improving antimicrobial prescribing: tools and interventions provided by stewardship programs. Enferm Infecc Microbiol Clin (2013) 0.76
High MICs for Vancomycin and Daptomycin and Complicated Catheter-Related Bloodstream Infections with Methicillin-Sensitive Staphylococcus aureus. Emerg Infect Dis (2016) 0.76
[Glycopeptide-resistant Enterococcus faecium in a hospital in northern Spain. Molecular characterization and clinical epidemiology]. Enferm Infecc Microbiol Clin (2009) 0.76
Long-term outcome of patients after a single interruption of antiretroviral therapy: a cohort study. BMC Res Notes (2012) 0.76
Bilateral pneumonia by Mycobacterium aurum in a patient receiving infliximab therapy. J Infect (2008) 0.75
Reply to Fries et al and Valentin et al. Clin Infect Dis (2013) 0.75
[Prevention of neonatal infection by Streptococcus agalactiae. A firmly-established topic]. Enferm Infecc Microbiol Clin (2003) 0.75
Screening for pandemic (H1N1) 2009 virus among hospital staff, Spain. Emerg Infect Dis (2011) 0.75
[Bone-integration and bone-biomimicry of dental implants: role of peri-implant infections]. Enferm Infecc Microbiol Clin (2009) 0.75
Therapy for methicillin-resistant Staphylococcus aureus. N Engl J Med (2006) 0.75